Atossa Therapeutics (FRA:YAG2) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Atossa Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Atossa Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Atossa Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:YAG2' s Cash-to-Debt Range Over the Past 10 Years
Min: 92.65 Med: No Debt Max: 140041
Current: No Debt

During the past 13 years, Atossa Therapeutics's highest Cash to Debt Ratio was 140041.00. The lowest was 92.65. And the median was No Debt.

FRA:YAG2's Cash-to-Debt is ranked better than
99.8% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs FRA:YAG2: No Debt

Atossa Therapeutics Cash-to-Debt Historical Data

The historical data trend for Atossa Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Atossa Therapeutics Cash-to-Debt Chart

Atossa Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

251.62

2,167.53

No Debt

Atossa Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Atossa Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Atossa Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Cash-to-Debt falls into.

Atossa Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Atossa Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Atossa Therapeutics had no debt ⁽¹⁾.

Atossa Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Atossa Therapeutics had no debt ⁽¹⁾.

Atossa Therapeutics (FRA:YAG2) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Atossa Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics (FRA:YAG2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics (FRA:YAG2) Headlines

No Headlines

Atossa Therapeutics (FRA:YAG2) Cash-to-Debt : No Debt (1) (As of Mar. 2024)